Exelon Corporation EXC Evolving Regulatory Capital Expenditure and Valuation Narratives Signal Mixed NearTerm Headwinds and LongTerm Upside ANVS Annovis Bio shares drop 387 after Q4 2025 wider loss misses analyst estimates by 114 RA Brookfield outlines new strategic priorities to boost income from its global real assets portfolio